Drug Approval | November 07, 2022
Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Subscribe To Our Newsletter & Stay Updated
